VIVO diagnostics buys Genyca and leads the way in precision diagnostics

21/06/2019
Diego Gutiérrez
VIVO diagnostics buys Genyca and leads the way in precision diagnostics

The VIVO diagnóstico group takes a further step on its way to becoming the leading company in precision diagnostics in Spain. The company enters the field of genetics, and has just formalised the incorporation of the Genyca group, a laboratory specialising in molecular genetics.

VIVID DIAGNOSIS

VIVO diagnosis is a company specialising in diagnostic imaging and telemedicineThe new system will be able to combine in vivo and in vitro diagnostics through the use of artificial intelligence and Big Data tools.

To this end, it carries out an analysis based on prediction, prevention and personalisation. For the group, it is essential to identify any signs or probability of change in people's state of health as early as possible and as accurately as possible.

Ahora, además, gracias a Genyca, se va a incorporar pruebas de diagnóstico genético molecular para ayudar a estudiar el genoma de cada individuo, también denominado por algunos líderes del sector como el “software del cuerpo humano”.

However, this is not VIVO diagnostics' first operation on the market. Its journey towards precision diagnostics and service to the public began two years ago with two other operations. mergers and acquisitions . The following are some of the issues that we set out below.

Dima Clinic

This clinic leader in breast pathology was the first of these. Dima Clinic has expert breast surgeons, radiologists and oncologists who offer comprehensive breast diagnosis and treatment.

Its experts assess each patient and her risk factors, using both mammography and breast ultrasound and obtaining the analysis of the results in an average of 2-3 days, as in these cases time is of the essence.

Fence

Después vino Cerco, una compañía referente en el mercado andaluz y with a strong presence in the world of clinical research.

In addition to mammography and breast ultrasound, its services include magnetic resonance imaging, CT and densitometry, with the aim of offering patients the highest diagnostic quality and reliability.

Lastest news

Webinar | Cómo maximizar el valor de tu empresa antes de vender

INFORMACIÓN IMPORTANTE: La inscripción y participación en los webinars es totalmente anónima para terceros Cómo maximizar el valor de tu empresa antes de vender Maximizar el valor de tu empresa antes de vender es, casi siempre, el trabajo más rentable que puede hacer...

The State of technology M&A in Spain | May 2026 Analysis

El M&A tecnológico en España registró en mayo de 2026 36 operaciones identificadas con un importe agregado conocido de aproximadamente 720,7 millones de euros. La cifra es una referencia mínima: 13 transacciones no hicieron público su importe. El mes combinó...

Notable technology M&A deals in Spain | Analysis: April 2026

The market for the sale and acquisition of technology companies in Spain once again saw particularly brisk activity in April 2026. The month saw significant deals in vertical software, cybersecurity, cloud computing, payments, artificial intelligence, telecommunications...

What does Constellation Software teach us about real value in tech M&A?

An analysis by Diego Gutiérrez Zarza, Partner at Baker Tilly Tech M&A For years, growth was enough to build value in a technology company. That is no longer the case. The market continues to pay a premium for good software companies, but it no longer rewards growth for its own sake...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?

    Request for information

    If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

    Or if you prefer, call us at:

    +34 946 42 41 42